AAN 2025: Evolving Therapeutic Approaches for Parkinson Disease
Movement disorders expert Fernando L Pagan, MD, provides commentary on several presentations of innovative therapies for Parkinson disease from the 2025 American Academy of Neurology Annual Meeting.
EP. 1: Real-World Impact of CSAI on Motor Fluctuations in PD
April 21st 2025Fernando L. Pagan, MD, discussed how continuous subcutaneous apomorphine infusion impacts long-term motor fluctuations in Parkinson disease, highlighting InfusON extension study findings on uninterrupted "good ON" time and reduced "OFF" periods as evidence of its real-world efficacy.
EP. 2: Patient Perspectives and Expert Tips on Managing CSAI Challenges in PD
April 24th 2025Pagan shared insights from InfusON patient interviews on the challenges and benefits of initiating CSAI therapy and discussed how expert roundtable recommendations can guide neurologists in managing skin nodules associated with treatment.
EP. 3: Using Amantadine ER and MAO-B Inhibitors to Optimize PD Care
April 28th 2025Pagan talked about discussed pharmacokinetic-pharmacodynamic data supporting the use of amantadine ER for dyskinesia in Parkinson disease and compared the safety profiles of rasagiline and safinamide to guide add-on therapy decisions.
